ERBB2 and breast carcinoma: Additionally, research has found that the inhibition of FGFR4 affects the expression of β-catenin/TCF4-SLC7A11 and FPN1, which has a significant impact on ferroptosis in HER2-positive breast cancer cells, thereby enhancing treatment sensitivity [10].